- Home
- Publications
- Publication Search
- Publication Details
Title
Renal effects of dapagliflozin in patients with type 2 diabetes
Authors
Keywords
-
Journal
Therapeutic Advances in Endocrinology and Metabolism
Volume 5, Issue 3, Pages 53-61
Publisher
SAGE Publications
Online
2014-07-25
DOI
10.1177/2042018814544153
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
- (2014) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition
- (2014) William T. Cefalu JOURNAL OF CLINICAL INVESTIGATION
- The hyperglycemic and hyperinsulinemic combo gives you diabetic kidney disease immediately. Focus on “Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney”
- (2013) Seung Hyeok Han et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
- (2013) M. A. Abdul-Ghani et al. DIABETES
- Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
- (2013) Richard E. Gilbert KIDNEY INTERNATIONAL
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Type 2 Diabetes Mellitus
- (2013) Shawn Riser Taylor et al. PHARMACOTHERAPY
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
- (2013) Usha Panchapakesan et al. PLoS One
- Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus
- (2012) Steven G. Coca et al. ARCHIVES OF INTERNAL MEDICINE
- Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
- (2012) Jean Whaley et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
- (2011) Scott C. Thomson et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
- (2011) Giovanni Musso et al. ANNALS OF MEDICINE
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
- (2011) K. Strojek et al. DIABETES OBESITY & METABOLISM
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
- (2011) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Serum Uric Acid as a New Player in the Development of Diabetic Nephropathy
- (2011) Peter Hovind et al. JOURNAL OF RENAL NUTRITION
- Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with Type 2 diabetes mellitus
- (2011) John E Gerich et al. Expert Review of Clinical Pharmacology
- Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
- (2010) M. Goicoechea et al. Clinical Journal of the American Society of Nephrology
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
- (2010) Jian Chen et al. Diabetes Therapy
- Glucose Control, the Kidney, and Potential Treatments for Diabetes: More to the Story
- (2009) Joel Ehrenkranz AMERICAN JOURNAL OF KIDNEY DISEASES
- Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice
- (2009) Ryuichi Moriya et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Solute carrier family 2, member 9 and uric acid homeostasis
- (2009) Chris Cheeseman CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts
- (2009) F. Afshinnia et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
- Phlorizin Prevents Glomerular Hyperfiltration but not Hypertrophy in Diabetic Rats
- (2008) Slava Malatiali et al. Experimental Diabetes Research
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started